Sort   by:  
 Page size 
UnknownPoly (ADP-ribose) polymerase inhibitors: recent advances and future development.
Not available
S-EPMC4517072 | biostudies-literature
UnknownSecondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.
Not available
S-EPMC3157963 | biostudies-literature
UnknownSafety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
Not available
S-EPMC5493052 | biostudies-literature
Sort   by:  
 Page size